Status:

TERMINATED

Effect of Enteral Nutrition Support for Critically Ill Patients

Lead Sponsor:

Abbott Nutrition

Conditions:

Respiratory Distress Syndrome,Adult

Acute Lung Injury

Eligibility:

All Genders

18-70 years

Phase:

PHASE3

Brief Summary

To determine whether specialized enteral nutrition support can improve oxygenation status in critically ill patients with acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) comparin...

Eligibility Criteria

Inclusion

  • Male or non-pregnant female.
  • ALI or ARDS
  • PaO2/FiO2 \> 100 and ≤ 300 torr.
  • Evidence of bilateral pulmonary infiltrates/opacity on chest radiograph.
  • Enteral access
  • Systemic inflammatory response syndrome (SIRS) - two or more of the following must be present:
  • Body temperature less than 36°C or greater than 38°C
  • Heart rate \> 90 beats per minute
  • Tachypnea with \> 20 breaths per minute; or an arterial partial pressure of carbon dioxide \< 4.3 kPa (32 mmHg)
  • White blood cell count \< 4000 cells/mm³ or \> 12,000 cells/mm³; or the presence of \> 10% immature neutrophils.

Exclusion

  • Dialysis for renal failure
  • Unable to initiate Enteral feeding within 48 hours since all inclusion criteria met.
  • Anticipated life expectancy less than 24 hours.
  • Patient with severe chronic liver disease
  • Neuromuscular disease that impairs ability to ventilate without assistance
  • Head trauma and/or drowning with a Glasgow coma score of 5
  • Receiving intravenous lipid emulsions from parenteral nutrition within 12 hours of baseline.
  • Receiving propofol
  • Airway reconstructive surgery.
  • Malignancy or irreversible disease for which 6-month mortality is greater than 50%.
  • Burns greater than 25% total body surface area.
  • Unwillingness or inability to utilize the ARDS network ventilation protocol.
  • HIV positive.
  • Chronic mechanical ventilation.
  • Severe, acute pancreatitis.
  • Refractory shock
  • Congestive heart failure with pulmonary edema as the primary cause of hypoxemia.
  • Acute myocardial infarction or cardiac surgery within 7 days.
  • Solid organ transplant.
  • INR \> 5.0 or platelet count \< 30,000/mm3 or history of bleeding disorder.
  • Intracranial hemorrhage within the past 30 days.

Key Trial Info

Start Date :

April 1 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2011

Estimated Enrollment :

84 Patients enrolled

Trial Details

Trial ID

NCT01464853

Start Date

April 1 2010

End Date

May 1 2011

Last Update

November 4 2011

Active Locations (9)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (9 locations)

1

1st City Clinical Emergency Hospital n.a. E.E. Volosevich

Arkhangelsk, Russia, 163001

2

City Clinical Hospital #2

Krasnodar, Russia, 350012

3

Krasnoyarsk State Medical University n.a. Prof V.F. Voyno-Yasenetskogo

Krasnoyarsk, Russia, 660022

4

Central Clinical Hospital #1

Moscow, Russia, 125367